Skip to Content

Aquestive Therapeutics, Inc.

Securities Class Action

  • Date:
  • 1/20/2026
  • Company Name:
  • Aquestive Therapeutics, Inc.
  • Stock Symbol:
  • AQST
  • Status:
  • Filed
  • Filing Date:
  • 3/5/2026
  • Court:
  • U.S. District Court: District of New Jersey

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ:AQST) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired Aquestive securities between June 16, 2025 to January 8, 2026, both dates inclusive (the “Class Period”). Investors have until May 4, 2026  to apply to the Court to be appointed as lead plaintiff in the lawsuit.


According to the complaint, during the class period, defendants created the false impression that Aquestive was on track to receive approval for the Company’s New Drug Application (NDA) for Anaphylm by the January 31, 2026 Prescription Drug User Fee Act (PDUFA) date. In contrast, the FDA identified deficiencies with Aquestive’s NDA for Anaphylm precluding labeling discussions and post-marketing commitments. For the FDA to grant approval for any NDA, any deficiencies must be remedied, therefore the launch of Anaphylm was delayed, indicating that Aquestive failed to obtain approval for Anaphylm by the PDUFA date. 

Plaintiff alleges that on January 9, 2026, Aquestive announced that the Company was in receipt of a letter from the FDA identifying deficiencies that precluded labeling discussions for Anaphylm. Moreover, Aquestive revealed that the letter from the FDA confirmed that the Agency’s review of Anaphylm NDA was ongoing and no final decision had been made, which effectively delayed the approval of Anaphylm well beyond the January 31, 2026 PDUFA date. On this news, the price of Aquestive’s common stock declined over 37%, from a closing market price of $6.21 per share on January 8, 2026, to $3.91 per share on January 9, 2026.


If you purchased or otherwise acquired Aquestive shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out the form below.  There is no cost or obligation to you.

Contact Instructions
Please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com with any questions regarding the case.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Aquestive Therapeutics. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: